158 related articles for article (PubMed ID: 11906550)
21. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
[TBL] [Abstract][Full Text] [Related]
22. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
24. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
Tentes AA; Mirelis CG; Markakidis SK; Bekiaridou KA; Bougioukas IG; Xanthoulis AI; Tsalkidou EG; Zafiropoulos GH; Nikas IH
Int J Gynecol Cancer; 2006; 16(2):490-5. PubMed ID: 16681716
[TBL] [Abstract][Full Text] [Related]
27. Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
Arikan SK; Kasap B; Yetimalar H; Yildiz A; Sakarya DK; Tatar S
Asian Pac J Cancer Prev; 2014; 15(15):6087-94. PubMed ID: 25124578
[TBL] [Abstract][Full Text] [Related]
28. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture.
Mizuno M; Kikkawa F; Shibata K; Kajiyama H; Suzuki T; Ino K; Kawai M; Mizutani S
Oncology; 2003; 65(1):29-36. PubMed ID: 12837980
[TBL] [Abstract][Full Text] [Related]
29. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
30. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.
Rosen B; Laframboise S; Ferguson S; Dodge J; Bernardini M; Murphy J; Segev Y; Sun P; Narod SA
Gynecol Oncol; 2014 Sep; 134(3):462-7. PubMed ID: 25026637
[TBL] [Abstract][Full Text] [Related]
31. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer.
Lee M; Kim SW; Lee SH; Paek J; Yim GW; Kim GE; Kim S; Kim JH; Kim YT; Nam EJ
Int J Gynecol Cancer; 2011 Aug; 21(6):1032-9. PubMed ID: 21738040
[TBL] [Abstract][Full Text] [Related]
33. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
[TBL] [Abstract][Full Text] [Related]
34. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
35. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
36. Outcome of interval debulking in advanced ovarian cancer patients.
Suprasert P; Tiyanon J; Kietpeerakool C
Asian Pac J Cancer Prev; 2008; 9(3):519-24. PubMed ID: 18990031
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of advanced ovarian cancer--is residual tumor diameter less than 2cm optimal?].
Shimizu Y; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Oct; 45(10):1129-35. PubMed ID: 8245592
[TBL] [Abstract][Full Text] [Related]
38. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.
Schwartz PE; Rutherford TJ; Chambers JT; Kohorn EI; Thiel RP
Gynecol Oncol; 1999 Jan; 72(1):93-9. PubMed ID: 9889037
[TBL] [Abstract][Full Text] [Related]
40. Individualized Treatment of Patients With Early-Stage Epithelial Ovarian Cancer After Incomplete Initial Surgery.
Tu H; Xiong Y; Huang H; Huang Y; Wan T; Deng T; Liu J
Int J Gynecol Cancer; 2016 Jan; 26(1):73-81. PubMed ID: 26569056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]